Literature DB >> 18497834

The ocular side effects of vigabatrin (Sabril): information and guidance for screening.

M J Hawker, N J Astbury.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18497834     DOI： 10.1038/eye.2008.139

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  10 in total

1.  Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.

Authors:  John M Wild; David L Fone; Saleh Aljarudi; Charlotte Lawthom; Philip E M Smith; Robert G Newcombe; Gareth D Lewis
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

2.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

3.  Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients.

Authors:  Betül Tuğcu; Mesrure Köseoğlu Bitnel; Fatma Selin Kaya; Betül Tekin Güveli; Dilek Ataklı
Journal:  Neurol Sci       Date:  2017-05-16       Impact factor: 3.307

4.  Vigabatrin Retinal Toxicity First Detected with Electroretinographic Changes: A Case Report.

Authors:  Dianne Barrett; Jin Yang; Tharikarn Sujirakul; Stephen H Tsang
Journal:  J Clin Exp Ophthalmol       Date:  2014

5.  Fundal changes in children receiving Vigabatrin.

Authors:  Devendra Mishra; Veena Kalra; Pradeep Venkatesh; Rachna Seth; Sheffali Gulati
Journal:  Indian J Pediatr       Date:  2011-03-15       Impact factor: 1.967

6.  Therapeutic effect of the mesenchymal stem cells on vigabatrin-induced retinopathy in adult male albino rat.

Authors:  Ayat Mahmoud Domouky; Walaa M Samy; Walaa A Rashad
Journal:  Anat Cell Biol       Date:  2022-06-30

7.  Transcriptome analysis in mice treated with vigabatrin identifies dysregulation of genes associated with retinal signaling circuitry.

Authors:  Dana Walters; Kara R Vogel; Madalyn Brown; Xutong Shi; Jean-Baptiste Roullet; K Michael Gibson
Journal:  Epilepsy Res       Date:  2020-06-20       Impact factor: 3.045

Review 8.  Anti-relapse medications: preclinical models for drug addiction treatment.

Authors:  Noushin Yahyavi-Firouz-Abadi; Ronald E See
Journal:  Pharmacol Ther       Date:  2009-08-13       Impact factor: 12.310

9.  Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential use-limiting visual field defects.

Authors:  Dana C Walters; Erwin E W Jansen; Garrett R Ainslie; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Jean-Baptiste Roullet; K M Gibson
Journal:  Pharmacol Res Perspect       Date:  2019-01-07

10.  Relationship between the area of isopters and Vigabatrin dosage during two years of observation.

Authors:  Katarzyna Nowomiejska; Marian Jedrych; Agnieszka Brzozowska; Konrad Rejdak; Tomasz Zarnowski; Michael J Koss; Katarzyna Ksiazek; Piotr Ksiazek; Ryszard Maciejewski; Anselm G Juenemann; Ulrich Schiefer; Robert Rejdak
Journal:  BMC Ophthalmol       Date:  2014-04-30       Impact factor: 2.209
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.